Skip to main content
Erschienen in: European Radiology 4/2022

10.01.2022 | Paediatric

Dynamic contrast-enhanced MR lymphangiography: feasibility of using ferumoxytol in patients with chronic kidney disease

verfasst von: Ensar Yekeler, Ganesh Krishnamurthy, Christopher L. Smith, Fernando A. Escobar, Erin Pinto, Jordan B. Rapp, Hansel J. Otero, Ammie M. White, Yoav Dori, David M. Biko

Erschienen in: European Radiology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the feasibility of direct intra-lymphatic administration of diluted ferumoxytol as a T1-positive contrast agent for dynamic contrast-enhanced MR lymphangiography (DCMRL) imaging of the central lymphatics in children with renal disease.

Methods

In vitro scan of dilute ferumoxytol was initially performed using time-resolved and high-resolution 3D gradient echo (GRE) sequences with short TE values (1 to 1.5 ms). A ferumoxytol concentration of 0.25 to 0.40 mg/mL was found to retain high signal in the T1-weighted sequences. DCMRL was then performed in 4 children with renal disease with the same 3D GRE sequences administrating diluted ferumoxytol via intra-mesenteric (IM), intra-hepatic (IH), and intra-nodal (IN) routes (6 to 9 mL to each site; average total dose of 0.75 mg/kg) by slow hand injection (0.5 to 1.0 mL/min). The signal-to-noise ratio (SNR) of the lymphatics was measured for quantitative evaluation.

Results

Ferumoxytol-enhanced DCMRL was technically successful in all patients. Contrast conspicuity within the lymphatics was sufficient without subtraction. The mean SNR was significantly higher than the muscle (50.1 ± 12.2 vs 13.2 ± 2.8; t = 15.9; p < .001). There were no short-term complications attributed to the administration of ferumoxytol in any of the four patients.

Conclusion

Magnetic resonance lymphangiography using ferumoxytol via IN, IH, and IM access is a new method to directly visualize the central lymphatic system and can be applied safely in patients with renal failure based on our preliminary report of four cases. Ferumoxytol-enhanced DCMRL shows diagnostic image quality by using 3D GRE sequences with short TE values and appropriate dilution of ferumoxytol.

Key Points

MR lymphangiography using ferumoxytol via intra-nodal, intra-hepatic, and intra-mesenteric access is a new method to directly visualize the central lymphatic system from the groin to the venous angle.
FDCMRL can be applied safely in patients with renal failure based on our preliminary report of four cases.
FDCMRL shows diagnostic image quality by using 3D GRE sequences with short TE values and appropriate dilution of the ferumoxytol.
Literatur
1.
Zurück zum Zitat Biko DM, Smith CL, Otero HJ et al (2019) Intrahepatic dynamic contrast MR lymphangiography: initial experience with a new technique for the assessment of liver lymphatics. Eur Radiol 29:5190–5196CrossRef Biko DM, Smith CL, Otero HJ et al (2019) Intrahepatic dynamic contrast MR lymphangiography: initial experience with a new technique for the assessment of liver lymphatics. Eur Radiol 29:5190–5196CrossRef
2.
Zurück zum Zitat Dori Y, Smith CL, DeWitt AG et al (2020) Intramesenteric dynamic contrast pediatric MR lymphangiography: initial experience and comparison with intranodal and intrahepatic MR lymphangiography. Eur Radiol 30:5777–5784CrossRef Dori Y, Smith CL, DeWitt AG et al (2020) Intramesenteric dynamic contrast pediatric MR lymphangiography: initial experience and comparison with intranodal and intrahepatic MR lymphangiography. Eur Radiol 30:5777–5784CrossRef
3.
Zurück zum Zitat Agarwal R, Brunelli SM, Williams K et al (2009) Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 24:856–863CrossRef Agarwal R, Brunelli SM, Williams K et al (2009) Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 24:856–863CrossRef
4.
Zurück zum Zitat Pasquini L, Napolitano A, Visconti E et al (2018) Gadolinium-based contrast agent-related toxicities. CNS Drugs 32:229–240CrossRef Pasquini L, Napolitano A, Visconti E et al (2018) Gadolinium-based contrast agent-related toxicities. CNS Drugs 32:229–240CrossRef
5.
Zurück zum Zitat McCormack PL (2012) Ferumoxytol: in iron deficiency anemia in adults with chronic kidney disease. Drugs 22(72):2013–2022CrossRef McCormack PL (2012) Ferumoxytol: in iron deficiency anemia in adults with chronic kidney disease. Drugs 22(72):2013–2022CrossRef
6.
Zurück zum Zitat Knobloch G, Colgan T, Wiens CN et al (2018) Relaxivity of ferumoxytol at 1.5 T and 3.0 T. Invest Radiol 53:257–263CrossRef Knobloch G, Colgan T, Wiens CN et al (2018) Relaxivity of ferumoxytol at 1.5 T and 3.0 T. Invest Radiol 53:257–263CrossRef
7.
Zurück zum Zitat Maki JH, Neligan PC, Briller N, Mitsumori LM, Wilson GJ (2016) Dark blood magnetic resonance lymphangiography using dual-agent relaxivity contrast (DARC-MRL): a novel method combining gadolinium and iron contrast agents. Curr Probl Diagn Radiol 45:174–179CrossRef Maki JH, Neligan PC, Briller N, Mitsumori LM, Wilson GJ (2016) Dark blood magnetic resonance lymphangiography using dual-agent relaxivity contrast (DARC-MRL): a novel method combining gadolinium and iron contrast agents. Curr Probl Diagn Radiol 45:174–179CrossRef
8.
Zurück zum Zitat Schieda N, Blaichman JI, Costa AF et al (2018) Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can Assoc Radiol J 69:136–150CrossRef Schieda N, Blaichman JI, Costa AF et al (2018) Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can Assoc Radiol J 69:136–150CrossRef
9.
Zurück zum Zitat Hassan N, Boville B, Reischmann D et al (2017) Intravenous ferumoxytol in pediatric patients with iron deficiency anemia. Ann Pharmacother 51:548–554CrossRef Hassan N, Boville B, Reischmann D et al (2017) Intravenous ferumoxytol in pediatric patients with iron deficiency anemia. Ann Pharmacother 51:548–554CrossRef
10.
Zurück zum Zitat Nguyen KL, Yoshida T, Kathuria-Prakash N et al (2019) Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. Radiology 293:554–564CrossRef Nguyen KL, Yoshida T, Kathuria-Prakash N et al (2019) Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. Radiology 293:554–564CrossRef
11.
Zurück zum Zitat Aghighi M, Pisani L, Theruvath AJ et al (2018) Ferumoxytol is not retained in kidney allografts in patients undergoing acute rejection. Mol Imaging Biol 20:139–149CrossRef Aghighi M, Pisani L, Theruvath AJ et al (2018) Ferumoxytol is not retained in kidney allografts in patients undergoing acute rejection. Mol Imaging Biol 20:139–149CrossRef
12.
Zurück zum Zitat Islam T, Wolf G (2009) The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10. Cancer Biomark 5:69–73CrossRef Islam T, Wolf G (2009) The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10. Cancer Biomark 5:69–73CrossRef
13.
Zurück zum Zitat Stoumpos S, Hennessy M, Vesey AT et al (2019) Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease. Eur Radiol 29:3543–3552CrossRef Stoumpos S, Hennessy M, Vesey AT et al (2019) Ferumoxytol magnetic resonance angiography: a dose-finding study in patients with chronic kidney disease. Eur Radiol 29:3543–3552CrossRef
14.
Zurück zum Zitat Nayak AB, Luhar A, Hanudel M et al (2015) High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol 30:515–521CrossRef Nayak AB, Luhar A, Hanudel M et al (2015) High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol 30:515–521CrossRef
15.
Zurück zum Zitat Nguyen KL, Han F, Zhou Z et al (2017) 4D MUSIC CMR: value-based imaging of neonates and infants with congenital heart disease. J Cardiovasc Magn Reson 3(19):40CrossRef Nguyen KL, Han F, Zhou Z et al (2017) 4D MUSIC CMR: value-based imaging of neonates and infants with congenital heart disease. J Cardiovasc Magn Reson 3(19):40CrossRef
16.
Zurück zum Zitat Ramasawmy R, Rogers T, Alcantar MA et al (2018) Blood volume measurement using cardiovascular magnetic resonance and ferumoxytol: preclinical validation. J Cardiovasc Magn Reson 10(20):62CrossRef Ramasawmy R, Rogers T, Alcantar MA et al (2018) Blood volume measurement using cardiovascular magnetic resonance and ferumoxytol: preclinical validation. J Cardiovasc Magn Reson 10(20):62CrossRef
17.
Zurück zum Zitat Muehe AM, Siedek F, Theruvath AJ et al (2020) Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Theranostics 18(10):3612–3621CrossRef Muehe AM, Siedek F, Theruvath AJ et al (2020) Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Theranostics 18(10):3612–3621CrossRef
18.
Zurück zum Zitat Lee CU, Glockner JF, Hesley GK, Brinkman NJ, Tran NV (2020) Two non-gadolinium-based, innovative approaches to preoperative lymphangiography. Plast Reconstr Surg Glob Open 22(8):e2805CrossRef Lee CU, Glockner JF, Hesley GK, Brinkman NJ, Tran NV (2020) Two non-gadolinium-based, innovative approaches to preoperative lymphangiography. Plast Reconstr Surg Glob Open 22(8):e2805CrossRef
19.
Zurück zum Zitat Nie Y, Rui Y, Miao C, Li Q, Hu F, Gu H (2020) A stable USPIO capable for MR lymphography with ultra-low effective dosage. Nanomedicine 29:102233CrossRef Nie Y, Rui Y, Miao C, Li Q, Hu F, Gu H (2020) A stable USPIO capable for MR lymphography with ultra-low effective dosage. Nanomedicine 29:102233CrossRef
Metadaten
Titel
Dynamic contrast-enhanced MR lymphangiography: feasibility of using ferumoxytol in patients with chronic kidney disease
verfasst von
Ensar Yekeler
Ganesh Krishnamurthy
Christopher L. Smith
Fernando A. Escobar
Erin Pinto
Jordan B. Rapp
Hansel J. Otero
Ammie M. White
Yoav Dori
David M. Biko
Publikationsdatum
10.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 4/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-021-08448-x

Weitere Artikel der Ausgabe 4/2022

European Radiology 4/2022 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.